NASDAQ:WHWK Whitehawk Therapeutics Q2 2026 Earnings Report $4.70 +0.63 (+15.48%) Closing price 08/6/2026 04:00 PM EasternExtended Trading$4.57 -0.13 (-2.77%) As of 08/6/2026 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Whitehawk Therapeutics EPS ResultsActual EPS-$0.20Consensus EPS -$0.30Beat/MissBeat by +$0.10One Year Ago EPSN/AWhitehawk Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AWhitehawk Therapeutics Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Whitehawk Therapeutics Earnings HeadlinesWhitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial CancersAugust 6 at 12:51 PM | tipranks.comWhitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsAugust 6 at 8:00 AM | prnewswire.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. | Altimetry (Ad)Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 30, 2026 | americanbankingnews.comBiocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC DevelopmentJuly 7, 2026 | businesswire.com10 Hot Biotech Stocks Under $5 to BuyJune 10, 2026 | insidermonkey.comSee More Whitehawk Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Whitehawk Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Whitehawk Therapeutics and other key companies, straight to your email. Email Address About Whitehawk TherapeuticsAadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.View Whitehawk Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boeing's Comeback Is Building Momentum—Is It Real?Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is FallingBed Bath & Beyond Renovates: The Neighborhood BlueprintSpaceX: Love the Company, But the Stock Is a Harder CallDisney Sets Up for a Magical Year in 2027Astera Labs' Post-Earnings Pullback May Be Last Chance to Buy Below $360Why Analysts Are Bullish on a Stock That's Down 20% Upcoming Earnings Barrick Mining (8/10/2026)Simon Property Group (8/10/2026)SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)Nebius Group (8/12/2026)NetEase (8/13/2026)Brookfield (8/13/2026)NU (8/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
